Search

Your search keyword '"Mirabella, Massimiliano"' showing total 822 results
Start Over Author "Mirabella, Massimiliano"
822 results on '"Mirabella, Massimiliano"'

5. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Author

Chisari, Clara G., Bianco, Assunta, Brescia Morra, Vincenzo, Calabrese, Massimiliano, Capone, Fioravante, Cavalla, Paola, Chiavazza, Carlotta, Comi, Cristoforo, Danni, Maura, Filippi, Massimo, Iaffaldano, Pietro, Lanzillo, Roberta, Lo Fermo, Salvatore, Lucisano, Alessandra, Lugaresi, Alessandra, Lus, Giacomo, Marfia, Gerolama Alessandra, Marinelli, Fabiana, Mirabella, Massimiliano, Moiola, Lucia, Perin, Chiara, Realmuto, Sabrina, Toscano, Simona, Trojano, Maria, Vecchio, Domizia, and Patti, Francesco

Published
2023
Full Text
View/download PDF

6. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study

Author

Amato, Maria Pia, Bergamaschi, Roberto, Centonze, Diego, Mirabella, Massimiliano, Marfia, Girolama Alessandra, Totaro, Rocco, Lus, Giacomo, Brescia Morra, Vincenzo, Aguglia, Umberto, Comi, Cristoforo, Cavalla, Paola, Zaffaroni, Mauro, Rovaris, Marco, Grimaldi, Luigi Maria, Leoni, Stefania, Malucchi, Simona, Baldi, Eleonora, Romano, Marcello, Falcini, Mario, Perini, Paola, Assetta, Maurizio, Portaccio, Emilio, Sommacal, Sergio, Olivieri, Nunzio, Parodi, Franco, Todaro, Daniele Santo, Grassivaro, Nicoletta, Farina, Alberto, Mondino, Margaret Mary, Filippi, Massimo, and Trojano, Maria

Published
2023
Full Text
View/download PDF

7. NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Author

Signoriello, Elisabetta, Signori, Alessio, Lus, Giacomo, Romano, Giuseppe, Marfia, Girolama Alessandra, Landi, Doriana, Napoli, Francesca, D' Amico, Emanuele, Zanghí, Aurora, Di Filippo, Paola Sofia, Caliendo, Daniele, Carotenuto, Antonio, Spiezia, Antonio Luca, Fantozzi, Roberta, Centonze, Diego, Lucchini, Matteo, Mirabella, Massimiliano, Cocco, Eleonora, Frau, Jessica, Maniscalco, Giorgia Teresa, Di Battista, Maria Elena, Foschi, Matteo, Surcinelli, Andrea, Bonavita, Simona, Abbadessa, Gianmarco, Pasquali, Livia, Di Gregorio, Maria, Ferrò, Maria Teresa, Sormani, Maria Pia, and Schiavetti, Irene

Published
2024
Full Text
View/download PDF

9. Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience

Author

Ruggieri, Serena, Ianniello, Antonio, Copetti, Massimiliano, Altieri, Marta, Buscarinu, Maria Chiara, Centonze, Diego, Cortese, Antonio, De Giglio, Laura, Fantozzi, Roberta, Gasperini, Claudio, Grimaldi, Luigi M.E., Landi, Doriana, Marfia, Girolama A., Mirabella, Massimiliano, Nistri, Riccardo, Nociti, Viviana, Oddo, Oscar, Romano, Silvia, Salemi, Giuseppe, Tortorella, Carla, Pozzilli, Carlo, and Petracca, Maria

Published
2024
Full Text
View/download PDF

13. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.

Author

Amato, Anthony A, Hanna, Michael G, Machado, Pedro M, Badrising, Umesh A, Chinoy, Hector, Benveniste, Olivier, Karanam, Ananda Krishna, Wu, Min, Tankó, László B, Schubert-Tennigkeit, Agnes Annette, Papanicolaou, Dimitris A, Lloyd, Thomas E, Needham, Merrilee, Liang, Christina, Reardon, Katrina A, de Visser, Marianne, Ascherman, Dana P, Barohn, Richard J, Dimachkie, Mazen M, Miller, James AL, Kissel, John T, Oskarsson, Björn, Joyce, Nanette C, Van den Bergh, Peter, Baets, Jonathan, De Bleecker, Jan L, Karam, Chafic, David, William S, Mirabella, Massimiliano, Nations, Sharon P, Jung, Hans H, Pegoraro, Elena, Maggi, Lorenzo, Rodolico, Carmelo, Filosto, Massimiliano, Shaibani, Aziz I, Sivakumar, Kumaraswamy, Goyal, Namita A, Mori-Yoshimura, Madoka, Yamashita, Satoshi, Suzuki, Naoki, Aoki, Masashi, Katsuno, Masahisa, Morihata, Hirokazu, Murata, Kenya, Nodera, Hiroyuki, Nishino, Ichizo, Romano, Carla D, Williams, Valerie SL, Vissing, John, and Zhang Auberson, Lixin

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Accidental Falls, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Double-Blind Method, Female, Humans, Male, Middle Aged, Muscle Strength, Myositis, Inclusion Body, Time, Treatment Outcome, Walk Test, RESILIENT Study Extension Group, Neurosciences, Cognitive Sciences, Neurology & Neurosurgery, Clinical sciences
Abstract

ObjectiveTo assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM).MethodsParticipants (aged 36-85 years) who completed the core study (RESILIENT [Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients]) were invited to join an extension study. Individuals continued on the same treatment as in the core study (10 mg/kg, 3 mg/kg, 1 mg/kg bimagrumab or matching placebo administered as IV infusions every 4 weeks). The co-primary outcome measures were 6-minute walk distance (6MWD) and safety.ResultsBetween November 2015 and February 2017, 211 participants entered double-blind placebo-controlled period of the extension study. Mean change in 6MWD from baseline was highly variable across treatment groups, but indicated progressive deterioration from weeks 24-104 in all treatment groups. Overall, 91.0% (n = 142) of participants in the pooled bimagrumab group and 89.1% (n = 49) in the placebo group had ≥1 treatment-emergent adverse event (AE). Falls were slightly higher in the bimagrumab 3 mg/kg group vs 10 mg/kg, 1 mg/kg, and placebo groups (69.2% [n = 36 of 52] vs 56.6% [n = 30 of 53], 58.8% [n = 30 of 51], and 61.8% [n = 34 of 55], respectively). The most frequently reported AEs in the pooled bimagrumab group were diarrhea 14.7% (n = 23), involuntary muscle contractions 9.6% (n = 15), and rash 5.1% (n = 8). Incidence of serious AEs was comparable between the pooled bimagrumab and the placebo group (18.6% [n = 29] vs 14.5% [n = 8], respectively).ConclusionExtended treatment with bimagrumab up to 2 years produced a good safety profile and was well-tolerated, but did not provide clinical benefits in terms of improvement in mobility. The extension study was terminated early due to core study not meeting its primary endpoint.Clinical trial registrationClinicaltrials.gov identifier NCT02573467.Classification of evidenceThis study provides Class IV evidence that for patients with sIBM, long-term treatment with bimagrumab was safe, well-tolerated, and did not provide meaningful functional benefit. The study is rated Class IV because of the open-label design of extension treatment period 2.

Published
2021

14. Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients

Author

Tredicine, Maria, Ria, Francesco, Poerio, Noemi, Lucchini, Matteo, Bianco, Assunta, De Santis, Federica, Valentini, Mariagrazia, De Arcangelis, Valeria, Rende, Mario, Stabile, Anna Maria, Pistilli, Alessandra, Camponeschi, Chiara, Nociti, Viviana, Mirabella, Massimiliano, Fraziano, Maurizio, and Di Sante, Gabriele

Published
2023
Full Text
View/download PDF

15. Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach

Author

Cicia Alessandra, Nociti Viviana, Bianco Assunta, De Fino Chiara, Carlomagno Vincenzo, Mirabella Massimiliano, and Lucchini Matteo

Subjects
neurosarcoidosis, longitudinally extensive transverse myelitis, trident sign, sarcoidosis, treatment, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Neurosarcoidosis is an uncommon and multiform clinical entity. Its presentation as an isolated longitudinal extensive transverse myelitis (LETM) is rare and challenging to identify. We report a case of LETM in a 60-year-old patient with no significant systemic symptoms nor relevant medical history. The peculiar spinal magnetic resonance imaging finding characterized by a posterior and central canal subpial contrast enhancement, the so-called “trident sign,” together with chest computed tomography scan and lymph node biopsy led to the diagnosis of sarcoidosis. We also discuss the main differential diagnoses of LETM and therapeutic options for sarcoidosis-related myelitis.

Published
2022
Full Text
View/download PDF

17. Covid-19 Outbreak in Italy: An Opportunity to Evaluate Extended Interval Dosing of Ocrelizumab in MS Patients (P2-6.010)

Author

Bisecco, Alvino, primary, Matrone, Federica, additional, Capobianco, Marco Alfonso Narduc, additional, De Luca, Giovanna, additional, Filippi, Massimo, additional, Granella, Franco, additional, Lus, Giacomo, additional, Marfia, Girolama Alessandra, additional, Mirabella, Massimiliano, additional, Patti, Francesco, additional, Trojano, Maria, additional, Mascolo, Agnese, additional, Copetti, Massimiliano, additional, Tedeschi, Gioacchino, additional, and Gallo, Antonio, additional

Published
2024
Full Text
View/download PDF

18. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy

Author

Lochmüller, Hanns, Behin, Anthony, Caraco, Yoseph, Lau, Heather, Mirabella, Massimiliano, Tournev, Ivailo, Tarnopolsky, Mark, Pogoryelova, Oksana, Woods, Catherine, Lai, Alexander, Shah, Jinay, Koutsoukos, Tony, Skrinar, Alison, Mansbach, Hank, Kakkis, Emil, and Mozaffar, Tahseen

Subjects
Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Delayed-Action Preparations, Distal Myopathies, Double-Blind Method, Female, Humans, Male, Middle Aged, Muscle Strength, Muscle, Skeletal, N-Acetylneuraminic Acid, Treatment Outcome, Young Adult, Clinical Sciences, Neurosciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy.MethodsUX001-CL301 was a phase 3, double-blind, placebo-controlled, randomized, international study evaluating the efficacy and safety of Ace-ER in patients with GNE myopathy. Participants who could walk ≥200 meters in a 6-minute walk test at screening were randomized 1:1, and stratified by sex, to receive Ace-ER 6 g/d or placebo for 48 weeks and assessed every 8 weeks. The primary endpoint was change in muscle strength over 48 weeks measured by upper extremity composite (UEC) score. Key secondary endpoints included change in lower extremity composite (LEC) score, knee extensor strength, and GNE myopathy-Functional Activity Scale (GNEM-FAS) mobility domain score. Safety assessments included adverse events (AEs), vital signs, and clinical laboratory results.ResultsEighty-nine patients were randomized (Ace-ER n = 45; placebo n = 44). Change from baseline to week 48 for UEC score between treatments did not differ (least square mean [LSM] Ace-ER -2.25 kg vs placebo -2.99 kg; LSM difference confidence interval [CI] 0.74 [-1.61 to 3.09]; p = 0.5387). At week 48, there was no significant difference between treatments for the change in key secondary endpoints: LEC LSM difference (CI) -1.49 (-5.83 to 2.86); knee extension strength -0.40 (-2.38 to 1.58); and GNEM-FAS mobility domain score -0.72 (-2.01 to 0.57). Gastrointestinal events were the most common AEs.ConclusionsAce-ER was not superior to placebo in improving muscle strength and function in patients with GNE myopathy.Classification of evidenceThis study provides Class I evidence that for patients with GNE myopathy, Ace-ER does not improve muscle strength compared to placebo.

Published
2019

20. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study.

Author

Borriello, Giovanna, Chisari, Clara Grazia, Maimone, Davide, Mirabella, Massimiliano, Paolicelli, Damiano, Assogna, Francesco, Caradonna, Sandro, and Patti, Francesco

Subjects
PHYSICAL mobility, WALKING speed, PATIENT reported outcome measures, DISABILITIES, LABOR productivity
Abstract

Patient-reported outcomes (PROs) are essential for understanding the effects of MS and its treatments on patients’ lives; they play an important role in multiple sclerosis (MS) research and practice. We present the protocol for an observational study to prospectively assess the effect of cladribine tablets on PROs and their correlation to disability and physical activity in adults with highly active relapsing MS switching from a first disease modifying drug (DMD) to cladribine tablets in routine clinical practice at study sites in Italy. The primary objective will be to evaluate changes from baseline in the impact of highly active MS on self-assessed physical functioning 52  weeks after the switch to cladribine tablets using the Multiple Sclerosis Impact Scale-29 (MSIS-29). Secondary objectives will include self-assessed psychological impact of highly active MS in daily life and general health after the switch to cladribine tablets as well as changes in cognitive function, anxiety, and depression symptoms. Additional PRO measures will include the Hospital Anxiety and Depression Scale (HADS), the EuroQoL 5-Dimension 5-Level (EQ-5D-5L), the Work Productivity and Activity Impairment Questionnaire: Multiple Sclerosis (WPAI:MS), and the Patient-Reported Outcomes Measurement Information System (PROMIS). Wearable devices will acquire activity data (step counts, walking speed, time asleep, and energy expenditure). Additional clinical, radiological, and laboratory data will be collected when available during routine management. The findings will complement data from controlled trials by providing insight from daily clinical practice into the effect of cladribine tablets on the patient’s experience and self-assessed impact of treatment on daily life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Hospital admissions from the emergency department of adult patients affected by myopathies

Author

Monforte, Mauro, primary, Torchia, Eleonora, additional, Bortolani, Sara, additional, Ravera, Beatrice, additional, Ricci, Enzo, additional, Silvestri, Gabriella, additional, Servidei, Serenella, additional, Primiano, Guido, additional, Mirabella, Massimiliano, additional, Sabatelli, Mario, additional, Mercuri, Eugenio, additional, Franceschi, Francesco, additional, Calabresi, Paolo, additional, Covino, Marcello, additional, and Tasca, Giorgio, additional

Published
2024
Full Text
View/download PDF

24. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study

Author

Bucello, Sebastiano, Annovazzi, Pietro, Ragonese, Paolo, Altieri, Marta, Barcella, Valeria, Bergamaschi, Roberto, Bianchi, Alessia, Borriello, Giovanna, Buscarinu, Maria Chiara, Callari, Graziella, Capobianco, Marco, Capone, Fioravante, Cavalla, Paola, Cavarretta, Rosella, Cortese, Antonio, De Luca, Giovanna, Di Filippo, Massimiliano, Dattola, Vincenzo, Fantozzi, Roberta, Ferraro, Elisabetta, Filippi, Maria Maddalena, Gasperini, Claudio, Grimaldi, Luigi Maria Edoardo, Landi, Doriana, Re, Marianna Lo, Mallucci, Giulia, Manganotti, Paolo, Marfia, Girolama Alessandra, Mirabella, Massimiliano, Perini, Paola, Pisa, Marco, Realmuto, Sabrina, Russo, Margherita, Tomassini, Valentina, Torri-Clerici, Valentina Liliana Adriana, Zaffaroni, Mauro, Zuliani, Cristina, Zywicki, Sofia, Filippi, Massimo, and Prosperini, Luca

Published
2021
Full Text
View/download PDF

25. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

Author

De Mercanti, Stefania Federica, Signori, Alessio, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Abbadessa, Gianmarco, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Capra, Ruggero, Sormani, Maria Pia, and Clerico, Marinella

Published
2021
Full Text
View/download PDF

26. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis

Author

Lucchini, Matteo, Prosperini, Luca, Buscarinu, Maria Chiara, Centonze, Diego, Conte, Antonella, Cortese, Antonio, Elia, Giorgia, Fantozzi, Roberta, Ferraro, Elisabetta, Gasperini, Claudio, Ianniello, Antonio, Landi, Doriana, Marfia, Girolama Alessandra, Nociti, Viviana, Pozzilli, Carlo, Salvetti, Marco, Tortorella, Carla, and Mirabella, Massimiliano

Published
2021
Full Text
View/download PDF

28. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

Author

Zanghì, Aurora, Gallo, Antonio, Avolio, Carlo, Capuano, Rocco, Lucchini, Matteo, Petracca, Maria, Bonavita, Simona, Lanzillo, Roberta, Ferraro, Diana, Curti, Erica, Buccafusca, Maria, Callari, Graziella, Barone, Stefania, Pontillo, Giuseppe, Abbadessa, Gianmarco, Di Francescantonio, Valeria, Signoriello, Elisabetta, Lus, Giacomo, Sola, Patrizia, Granella, Franco, Valentino, Paola, Mirabella, Massimiliano, Patti, Francesco, and D’Amico, Emanuele

Published
2021
Full Text
View/download PDF

29. Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?

Author

Bianco, Assunta, Di Sante, Gabriele, Colò, Francesca, De Arcangelis, Valeria, Cicia, Alessandra, Del Giacomo, Paola, De Bonis, Maria, Morganti, Tommaso Giuseppe, Carlomagno, Vincenzo, Lucchini, Matteo, Minucci, Angelo, Calabresi, Paolo, and Mirabella, Massimiliano

Subjects
COVID-19 vaccines, HAPLOTYPES, COVID-19 pandemic, MULTIPLE sclerosis, NATURE & nurture
Abstract

A few cases of multiple sclerosis (MS) onset after COVID-19 vaccination have been reported, although the evidence is insufficient to establish causality. The aim of this study is to compare cases of newly diagnosed relapsing–remitting MS before and after the outbreak of the COVID-19 pandemic and the impact of COVID-19 vaccination. Potential environmental and genetic predisposing factors were also investigated, as well as clinical patterns. This is a single-centre retrospective cohort study including all patients who presented with relapsing–remitting MS onset between January 2018 and July 2022. Data on COVID-19 vaccination administration, dose, and type were collected. HLA-DRB1 genotyping was performed in three subgroups. A total of 266 patients received a new diagnosis of relapsing–remitting MS in our centre, 143 before the COVID-19 pandemic (until and including March 2020), and 123 during the COVID-19 era (from April 2020). The mean number of new MS onset cases per year was not different before and during the COVID-19 era and neither were baseline patients' characteristics, type of onset, clinical recovery, or radiological patterns. Fourteen (11.4%) patients who subsequently received a new diagnosis of MS had a history of COVID-19 vaccination within one month before symptoms onset. Patients' characteristics, type of onset, clinical recovery, and radiological patterns did not differ from those of patients with non-vaccine-related new diagnoses of MS. The allele frequencies of HLA-DRB1*15 were 17.6% and 22.2% in patients with non-vaccine-related disease onset before and during the COVID-19 era, respectively, while no case of HLA-DRB1*15 was identified among patients with a new diagnosis of MS post-COVID-19 vaccine. In contrast, HLA-DRB1*08+ or HLA-DRB1*10+ MS patients were present only in this subgroup. Although a causal link between COVID-19 vaccination and relapsing–remitting MS cannot be detected, it is interesting to note and speculate about the peculiarities and heterogeneities underlying disease mechanisms of MS, where the interactions of genetics and the environment could be crucial also for the follow-up and the evaluation of therapeutic options. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab

Author

Landi, Doriana, Grimaldi, Alfonso, Bovis, Francesca, Ponzano, Marta, Fantozzi, Roberta, Buttari, Fabio, Signoriello, Elisabetta, Lus, Giacomo, Lucchini, Matteo, Mirabella, Massimiliano, Cellerino, Maria, Inglese, Matilde, Cola, Gaia, Nicoletti, Carolina Gabri, Mataluni, Giorgia, Centonze, Diego, and Marfia, Girolama Alessandra

Published
2022
Full Text
View/download PDF

31. Different HLA genotype pattern in patients with Multiple Sclerosis onset after COVID-19 vaccine.

Author

Bianco, Assunta, primary, Sante, Gabriele Di, additional, Colò, Francesca, additional, De Arcangelis, Valeria, additional, Cicia, Alessandra, additional, Giacomo, Paola Del, additional, De Bonis, Maria, additional, Morganti, Tommaso, additional, Carlomagno, Vincenzo, additional, Lucchini, Matteo, additional, Minucci, Angelo, additional, Calabresi, Paolo, additional, and Mirabella, Massimiliano, additional

Published
2023
Full Text
View/download PDF

32. Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study

Author

Bisecco, Alvino, Fornasiero, Arianna, Bianco, Assunta, Cortese, Antonio, D’Amico, Emanuele, Mataluni, Giorgia, Sinisi, Leonardo, Spitaleri, Daniele, Docimo, Renato, Buscarinu, Maria Chiara, Mirabella, Massimiliano, Crisafulli, Sebastiano Giuseppe, Zanghì, Aurora, Nicoletti, Carolina Gabri, Salvetti, Marco, Baione, Viola, Patti, Francesco, Marfia, Alessandra Girolama, Sibilia, Grazia, Scarano, Valentina, Orlando, Davide, Stabile, Giovanni, Tedeschi, Gioacchino, and Gallo, Antonio

Published
2022
Full Text
View/download PDF

33. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod

Author

Vanoli, Emilio, Montano, Nicola, De Angelis, Giuseppe, Badilini, Fabio, Mirabella, Massimiliano, Bonavita, Simona, Patti, Francesco, Bianco, Assunta, Sparaco, Maddalena, Chisari, Clara, Laroni, Alice, Frigerio, Francesca, Bartezaghi, Marta, Rossi, Silvia, Turrini, Renato, and Mancardi, Gianluigi

Published
2019
Full Text
View/download PDF

34. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Author

Sormani, Maria Pia, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Brescia Morra, Vincenzo, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri Rossi, Beatrice Maria, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Roberto, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, dʼAmbrosio, Alessandro, DʼAmico, Emanuele, Danni, Maura Chiara, dʼArma, Alessia, Dattola, Vincenzo, de Biase, Stefano, Luca, Giovanna De, Mercanti, Stefania Federica De, De Mitri, Paolo, De Stefano, Nicola, Cava, Marco Della, Napoli, Mario di, Sapio, Alessia Di, Docimo, Renato, Dutto, Anna, Evangelista, Luana, Fanara, Salvatore, Diana, Ferraro, Ferrò, Maria Teresa, Fioretti, Cristina, Fratta, Mario, Frau, Jessica, Fronza, Marzia, Furlan, Roberto, Gajofatto, Alberto, Gallo, Antonio, Gallo, Paolo, Gasperini, Claudio, Ghazaryan, Anna, Giometto, Bruno, Gobbin, Francesca, Govone, Flora, Granella, Franco, Grange, Erica, Grasso, Maria Grazia, Guareschi, Angelica, Guaschino, Clara, Guerrieri, Simone, Guidetti, Donata, Iaffaldano, Pietro, Ianniello, Antonio, Iasevoli, Luigi, Imperiale, Daniele, Infante, Maria Teresa, Iodice, Rosa, Iovino, Aniello, Konrad, Giovanna, Landi, Doriana, Lanzillo, Roberta, Lapucci, Caterina, Lavorgna, Luigi, LʼEpiscopo, Maria Rita, Leva, Serena, Liberatore, Giuseppe, Lo Re, Marianna, Longoni, Marco, Lopiano, Leonardo, Lorefice, Lorena, Lucchini, Matteo, Lus, Giacomo, Maimone, Davide, Malentacchi, Maria, Mallucci, Giulia, Malucchi, Simona, Mancinelli, Chiara Rosa, Mancinelli, Luca, Manganotti, Paolo, Maniscalco, Giorgia Teresa, Mantero, Vittorio, Marangoni, Sabrina, Marastoni, Damiano, Marinelli, Fabiana, Marti, Alessandro, Boneschi, Filippo Martinelli, Masserano Zoli, Federco, Matta, Francesca, Mendozzi, Laura, Meucci, Giuseppe, Miante, Silvia, Miele, Giuseppina, Milano, Eva, Mirabella, Massimiliano, Missione, Rosanna, Moccia, Marcello, Moiola, Lucia, Montepietra, Sara, MontiBragadin, Margherita, Montini, Federico, Motta, Roberta, Nardone, Raffaele, Nicoletti, Carolina Gabri, Nobile-Orazio, Eduardo, Nozzolillo, Agostino, Onofrj, Marco, Orlandi, Riccardo, Palmieri, Anna, Paolicelli, Damiano, Pasquali, Livia, Pastò, Luisa, Pedrazzoli, Elisabetta, Petracca, Maria, Petrone, Alfredo, Piantadosi, Carlo, Pietroboni, Anna M, Pinardi, Federica, Ponzano, Marta, Portaccio, Emilio, Pozzato, Mattia, Pozzilli, Carlo, Prosperini, Luca, Protti, Alessandra, Ragonese, Paolo, Rasia, Sarah, Realmuto, Sabrina, Repice, Anna, Rigoni, Eleonora, Rilla, Maria Teresa, Rinaldi, Francesca, Romano, Calogero Marcello, Ronzoni, Marco, Rovaris, Marco, Ruscica, Francesca, Sabattini, Loredana, Salemi, Giuseppe, Saraceno, Lorenzo, Sartori, Alessia, Sartori, Arianna, Sbragia, Elvira, Scarano, Giuditta Ilaria, Scarano, Valentina, Schillaci, Valentina, Sessa, Maria, Sgarito, Caterina, Sibilia, Grazia, Siciliano, Gabriele, Signori, Alessio, Signoriello, Elisabetta, Sinisi, Leonardo, Sireci, Francesca, Sola, Patrizia, Solaro, Claudio, Sotgiu, Stefano, Sparaco, Maddalena, Stromillo, Maria Laura, Strumia, Silvia, Susani, Emanuela Laura, Tabiadon, Giulietta, Teatini, Francesco, Tomassini, Valentina, Tonietti, Simone, Torri, Clerici Valentina, Tortorella, Carla, Toscano, Simona, Totaro, Rocco, Trotta, Maria, Turano, Gabriella, Ulivelli, Monica, Valentino, Manzo, Vaula, Giovanna, Vecchio, Domizia, Vercellino, Marco, Verrengia, Elena Pinuccia, Vianello, Marika, Virgilio, Eleonora, Vitetta, Francesca, Vollaro, Stefano, Zaffaroni, Mauro, Zampolini, Mauro, Zarbo, Ignazio Roberto, and Zuliani, Luigi

Published
2022
Full Text
View/download PDF

36. Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study

Author

Prosperini, Luca, Cortese, Antonio, Lucchini, Matteo, Boffa, Laura, Borriello, Giovanna, Buscarinu, Maria Chiara, Capone, Fioravante, Centonze, Diego, De Fino, Chiara, De Pascalis, Daniela, Fantozzi, Roberta, Ferraro, Elisabetta, Filippi, Maria, Galgani, Simonetta, Gasperini, Claudio, Haggiag, Shalom, Landi, Doriana, Marfia, Girolama, Mataluni, Giorgia, Millefiorini, Enrico, Mirabella, Massimiliano, Monteleone, Fabrizia, Nociti, Viviana, Pontecorvo, Simona, Romano, Silvia, Ruggieri, Serena, Salvetti, Marco, Tortorella, Carla, Zannino, Silvana, and Di Battista, Giancarlo

Published
2020
Full Text
View/download PDF

37. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

Author

Clerico, Marinella, De Mercanti, Stefania Federica, Signori, Alessio, Iudicello, Marco, Cordioli, Cinzia, Signoriello, Elisabetta, Lus, Giacomo, Bonavita, Simona, Lavorgna, Luigi, Maniscalco, Giorgia Teresa, Curti, Erica, Lorefice, Lorena, Cocco, Eleonora, Nociti, Viviana, Mirabella, Massimiliano, Baroncini, Damiano, Mataluni, Giorgia, Landi, Doriana, Petruzzo, Martina, Lanzillo, Roberta, Gandoglia, Ilaria, Laroni, Alice, Frangiamore, Rita, Sartori, Arianna, Cavalla, Paola, Costantini, Gianfranco, Sormani, Maria Pia, and Capra, Ruggero

Published
2020
Full Text
View/download PDF

38. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Author

Hanna, Michael G, Badrising, Umesh A, Benveniste, Olivier, Lloyd, Thomas E, Needham, Merrilee, Chinoy, Hector, Aoki, Masashi, Machado, Pedro M, Liang, Christina, Reardon, Katrina A, de Visser, Marianne, Ascherman, Dana P, Barohn, Richard J, Dimachkie, Mazen M, Miller, James A L, Kissel, John T, Oskarsson, Björn, Joyce, Nanette C, Van den Bergh, Peter, Baets, Jonathan, De Bleecker, Jan L, Karam, Chafic, David, William S, Mirabella, Massimiliano, Nations, Sharon P, Jung, Hans H, Pegoraro, Elena, Maggi, Lorenzo, Rodolico, Carmelo, Filosto, Massimiliano, Shaibani, Aziz I, Sivakumar, Kumaraswamy, Goyal, Namita A, Mori-Yoshimura, Madoka, Yamashita, Satoshi, Suzuki, Naoki, Katsuno, Masahisa, Murata, Kenya, Nodera, Hiroyuki, Nishino, Ichizo, Romano, Carla D, Williams, Valerie S L, Vissing, John, Auberson, Lixin Zhang, Wu, Min, de Vera, Ana, Papanicolaou, Dimitris A, and Amato, Anthony A

Published
2019
Full Text
View/download PDF

39. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study.

Author

Ruggieri, Serena, Prosperini, Luca, Al-Araji, Sarmad, Annovazzi, Pietro Osvaldo, Bisecco, Alvino, Ciccarelli, Olga, De Stefano, Nicola, Filippi, Massimo, Fleischer, Vinzenz, Evangelou, Nikos, Enzinger, Christian, Gallo, Antonio, Garjani, Afagh, Groppa, Sergiu, Haggiag, Shalom, Khalil, Michael, Lucchini, Matteo, Mirabella, Massimiliano, Montalban, Xavier, and Pozzilli, Carlo

Subjects
MULTIPLE sclerosis, ORAL medication, ORAL drug administration, MEDICAL sciences, PROGNOSIS
Published
2024
Full Text
View/download PDF

40. Assessing treatment response to oral drugs for multiple sclerosis in real-world setting: a MAGNIMS Study

Author

Ruggieri, Serena, primary, Prosperini, Luca, additional, Al-Araji, Sarmad, additional, Annovazzi, Pietro Osvaldo, additional, Bisecco, Alvino, additional, Ciccarelli, Olga, additional, De Stefano, Nicola, additional, Filippi, Massimo, additional, Fleischer, Vinzenz, additional, Evangelou, Nikos, additional, Enzinger, Christian, additional, Gallo, Antonio, additional, Garjani, Afagh, additional, Groppa, Sergiu, additional, Haggiag, Shalom, additional, Khalil, Michael, additional, Lucchini, Matteo, additional, Mirabella, Massimiliano, additional, Montalban, Xavier, additional, Pozzilli, Carlo, additional, Preziosa, Paolo, additional, Río, Jordi, additional, Rocca, Maria A, additional, Rovira, Alex, additional, Stromillo, Maria L, additional, Zaffaroni, Mauro, additional, Tortorella, Carla, additional, and Gasperini, Claudio, additional

Published
2023
Full Text
View/download PDF

44. List of contributors

Author

Artukoglu, Bekir B., primary, Bachoo, Robert M., additional, Baranzini, Sergio E., additional, Benson, Merrill D., additional, Biglan, Kevin, additional, Blakeney, Iona, additional, Bloch, Michael H., additional, Brady, Melanie, additional, Brandsema, John F., additional, Broccolini, Aldobrando, additional, Brown, Robert H., additional, Cohen, Bernard, additional, Cole, Jordan J., additional, Comi, Anne M., additional, Crabbe, John C., additional, Darras, Basil T., additional, Dowling, Michael M., additional, Dunn, Walter, additional, Elroy-Stein, Orna, additional, Elsheikh, Bakri H., additional, Engel, Andrew G., additional, Fahn, Stanley, additional, Fasching, Liana, additional, Fears, Scott C., additional, Felling, Ryan J., additional, Ferner, Rosalie E., additional, Fink, John K., additional, Gillespie, Charles F., additional, Goldman, Alica M., additional, Goldman, Jill, additional, Gutmann, David H., additional, Haltia, Matti, additional, Hauser, Stephen L., additional, Hilbert, James E., additional, Iliopoulos, Othon, additional, Islam, Monica P., additional, Jenkins, Aaron K., additional, Jia, Xiaoming, additional, Jungbluth, Heinz, additional, Kayani, Saima N., additional, Khemani, Pravin, additional, Kirkham, Fenella J., additional, Kirkorian, A. Yasmine, additional, Kissel, John T., additional, Klein, Christine, additional, Kleopa, Kleopas A., additional, Kolb, Stephen J., additional, Konstantakou, Eumorphia, additional, Lambracht-Washington, Doris, additional, Lennington, Jessica B., additional, Lewis, David A., additional, Liang, Wen-Chen, additional, Lidstone, Paven A., additional, Lohmann, Katja, additional, Lombroso, Paul J., additional, Maher, Elizabeth A., additional, Marshall, Frederick, additional, McCann, Meghan, additional, McGarry, Andrew, additional, Meola, Giovanni, additional, Metelo, Ana, additional, Miller, Bruce L., additional, Mirabella, Massimiliano, additional, Mizutani, Shuki, additional, Mole, Sara E., additional, Moxley, Richard T., additional, Muntoni, Francesco, additional, Nemeroff, Charles B., additional, Nishino, Ichizo, additional, Noebels, Jeffrey L., additional, Pandolfo, Massimo, additional, Pevsner, Jonathan, additional, Ptáček, Louis, additional, Ralph, Jeffrey, additional, Renthal, William, additional, Reus, Victor I., additional, Roach, E. Steve, additional, Rosenberg, Roger N., additional, Savarese, Antonia M., additional, Sawyer, Russell P., additional, Scherer, Steven S., additional, Schiffmann, Raphael, additional, Schulz, Angela, additional, Sewry, Caroline, additional, Shakkottai, Vikram G., additional, Shinagawa, Shunichiro, additional, Singh, Pratibha, additional, Sreedharan, Jemeen, additional, Statland, Jeffrey M., additional, Szabo, Steven T., additional, Szuhay, Gabor, additional, Udd, Bjarne, additional, Vaccarino, Flora M., additional, Volk, David W., additional, Wilson, Kathleen S., additional, Xia, Weiming, additional, and Yu, Gang, additional

Published
2020
Full Text
View/download PDF

47. Effectiveness of Ocrelizumab in Primary PrOgRessive mulTiple sclerosis: a mUlticeNter, retrospective, real-world sTudY (OPPORTUNITY)

Author

Grazia, Clara, primary, Bianco, Assunta, additional, Morra, Vincenzo Brescia, additional, Calabrese, Massimiliano, additional, Capone, Fioravante, additional, Cavalla, Paola, additional, Comi, Cristoforo, additional, Danni, Maura Chiara, additional, Filippi, Massimo, additional, Iaffaldano, Pietro, additional, Lanzillo, Roberta, additional, Fermo, Salvatore Lo, additional, Lucisano, Alessandra, additional, Lus, Giacomo, additional, Marfia, Gerolama Alessandra, additional, Marinelli, Fabiana, additional, Mirabella, Massimiliano, additional, Perin, Chiara, additional, Moiola, Lucia, additional, Realmuto, Sabrina, additional, Toscano, Simona, additional, Trojano, Maria, additional, Vecchio, Domizia, additional, and Patti, Francesco, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results